Cochrane Summariesbeta

Independent high-quality evidence for health care decision making
  • English
  • Deutsch AchtungWenn Sie die Sprache wechseln, gehen Ihre derzeitigen Suchergebnisse verloren!
  • Español WarningWhen switching the language you will loose your search results!

Adjustable maintenance dosing of combination inhaled steroid and long-acting beta agonist for asthma

Currently sorted by: Best match

Search results: 29

  1. Combination therapy of inhaled steroids and long-acting beta-agonists versus long-acting beta-agonists alone for chronic obstructive pulmonary disease
    Combinations of two classes of medication in one inhaler have been developed to treat people with COPD as this may make it easier to take the medication than using separate inhalers. Two types of combined inhaler exist currently: budesonide/formoterol (BDF - 'Symbicort'), and fluticasone/salmeterol (FPS - 'Advair', 'Viani' or 'Seretide'). The results ...
  2. The addition of long-acting beta2-agonists to inhaled steroids compared to higher doses of inhaled steroids alone as maintenance treatment for chronic asthma
    When asthma is inadequately controlled with inhaled corticosteroids, either adding medication such as long-acting beta2-agonists (LABAs) or increasing the dose of inhaled corticosteroids is recommended. The purpose of this review was to establish the benefits and safety of adding long-acting beta2-agonists or increasing the dose of inhaled corticosteroids ...
  3. The effect of adding a long-acting beta-agonist to inhaled steroids in people not previously treated with inhaled steroids
    In patients with asthma who require daily anti-inflammatory therapy, there is insufficient evidence to support initiating therapy with a combination of inhaled corticosteroids (ICS) and long-acting ß2-agonist (LABA) rather than with inhaled corticosteroids alone. Most consensus statements recommend the addition of LABA as second line therapy, only in ...
  4. Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children
    The combination of long acting beta agonist (LABA) with inhaled corticosteroid (ICS) is used frequently in asthma and a benefit from adding LABA to ICS has been described. This review compared reduced dose (mean 60% reduction in inhaled steroid) ICS/LABA combination to either a fixed moderate/high dose ICS or a reduced/tapering ICS dose. In adults with ...
  5. Different combinations of inhaled steroids and long-acting beta-agonists for chronic asthma (fluticasone/salmeterol versus budesonide/formoterol)
    People with persistent asthma often require an additional treatment to regular inhaled steroids. Some preparations of long-acting beta-agonists are delivered in the same inhaler device as the inhaled corticosteroids. Inhaled steroids help to treat inflammation of the airway and long-acting beta-agonists help the airway to relax, improving symptoms and ...
  6. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma
    The use of long-acting ß2-agonists (LABAs) as 'add-on' medication to inhaled corticosteroids is recommended for poorly-controlled asthma where asthma exacerbations may require additional treatment with oral steroids. The purpose of this review was to assess the efficacy and safety of adding long-acting ß2-agonists to inhaled corticosteroids in asthmatic ...
  7. What are the effects of long-acting beta 2 -agonists compared with anti-leukotrienes when added to inhaled steroids?
    People who continue to experience asthma symptoms despite regularly taking inhaled corticosteroids are a challenge for management. It is not clear whether the addition of a long-acting beta2-agonist (LABA) such as formoterol or salmeterol would provide more benefit in comparison with an oral anti-leukotriene agent (LTRA), for example zafirlukast or ...
  8. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children
    Most consensus statements recommend the use of long-acting ß2-agonists (LABA) as adjunct therapy to inhaled corticosteroids for poorly controlled asthma. The purpose of this review was to identify the benefits and safety profile of adding long-acting ß2-agonists to inhaled corticosteroids in asthmatic children. Based on the identified paediatric randomised ...
  9. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma
    This review compared three asthma medications, salmeterol, formoterol (both long acting beta-agonists) and theophylline. These medications are used to help control symptoms of asthma, especially those which occur during the night. This review found that salmeterol showed a greater improvement in lung function, and reduced the need for extra short-term ...
  10. Combination therapy of inhaled steroids and long-acting beta-agonists versus inhaled steroids alone
    Combinations of two classes of medication (long-acting beta-agonists and inhaled corticosteroids) in one inhaler have been developed to treat people with COPD as it may make it easier to take the medication . Two brands of combined inhaler exist currently: budesonide/formoterol (BDF - 'Symbicort'), and fluticasone/salmeterol (FPS - 'Advair' or 'Seretide'). ...

Pages

Summaries per page: